ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Needs To Move Quicker On Funding Jot New Leads, Rauscher Says; Harley Dirks Quits

October 15, 1976

CTEP Director Friedman Adds To Article On Minority Initiative

March 23, 1990

In Brief: NCI Claim “Major Finding” In Treatment Of Soft Tissue Sarcoma With Three Modalities; 93% Survival

October 9, 1981

Guest Editorial – Interlocking Tragedies: Lance Armstrong and CPRIT

February 15, 2013

Obese Men With Benign Biopsy At High Risk for Prostate Cancer

April 26, 2013

In Brief: NCI, OMB Heading For November Confrontation Over Hawaii, Papanicolaou Construction Funds

October 17, 1975